In an open-label, multicenter phase III study, ensartinib, an oral tyrosine kinase inhibitor of ALK, showed systemic and central nervous system improvement for patients with ALK-positive NSCLC. The gene discussed is ALK; the disease is non-small cell lung carcinoma.